Navigation Links
Oramed to Present at Upcoming Conferences
Date:9/3/2014

U.S. Food and Drug Administration.  In addition the company is developing an oral GLP-1 analog capsule (ORMD-0901).

For more information, the content of which is not part of this press release, please visit http://www.oramed.com

Forward-looking statements:  This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, we are using forward-looking statements when we discuss our clinical trials, including the expected timing thereof, and revolutionizing the treatment of diabetes with our products. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applica
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oramed Pharmaceuticals Reports Last Patient Out in Phase IIa Trial for ORMD-0801 in Type 1 Diabetes
2. Oramed to Participate in Barclays Israel Biotech Corporate Day in Zurich on September 30, 2013
3. Oramed Submits Pre-IND Package to FDA for ORMD-0901 (oral exenatide), an Oral GLP-1 Analog for the Treatment of Type 2 Diabetes
4. Oramed CEO to be Panelist at BIO International Convention Breakout Session on Israel Becoming Biotech Leader
5. Oramed Pharmaceuticals Moves Forward with Investigational New Drug Application for Oral Insulin
6. Bioassociate Announces Initiation of Coverage on Oramed Pharmaceuticals, Inc.
7. Oramed Pharmaceuticals Announces Reverse Stock Split
8. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
9. Data Presented At Breast Cancer Symposium 2014 Validates Biscayne Pharmaceuticals GHRH Target In Breast Cancer
10. Synthetic Biologics to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City
11. Oncothyreon to Present at Rodman & Renshaw Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 27, 2015  Northwest Biotherapeutics, Inc. ... developing DCVax® personalized immune therapies for cancer, announced today ... Officer of the Company, will be making an Industry ... in Chicago on Saturday, May ... the Industry Expert Theater in McCormick Place. ...
(Date:5/27/2015)... 27, 2015  Ceres, Inc. (Nasdaq: CERE ), ... patent for a genetic sequence derived from soybean, covering ... product development and plant transformation. The company believes that ... that are the target of a class of commercial ... commercial license to the innovation, including an opportunity for ...
(Date:5/27/2015)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII ), ... innovative therapies primarily in the areas of dermatology ... of the Company,s Series A and Series A-1 ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO At March 31, ... Series A Preferred Stock and Series A-1 Preferred ...
(Date:5/27/2015)... 2015 ­ Caris Life Sciences®, a leading ... medicine, today announced it has appointed the Levine Cancer ... excellence site in the Caris Centers of Excellence for ... Institute is one of the largest cancer care providers ... cancer patients annually. Derek Raghavan , M.D., Ph.D., ...
Breaking Biology Technology:NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 3Ceres Awarded Patent for Innovation in Soybean 2Ceres Awarded Patent for Innovation in Soybean 3RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 2Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 4
... Researchers at the National Institute of Standards and Technology ... complex viscosity measurementscritical data for a wide variety of ... sizes as small as a few nanoliters. Currently a ... valuable tool for biotechnologists studying minute quantities of complex ...
... MATK ) today announced its financial results for ... quarter were $117.2 million, up 51% from $77.8 million in ... $11.9 million, or $0.35 per diluted share, for the third ... $8.9 million, or $0.27 per diluted share, for the third ...
... , the semiconductor sequencing company, today announced that it ... Pioneers for 2011. The winning companies were chosen from a field ... expected to have on the future of business and society. ... and CEO, was selected to represent the company at Davos in ...
Cached Biology Technology:Micro rheometer is latest Lab On a Chip device 2Martek Announces Third Quarter FY 2010 Financial Results 2Martek Announces Third Quarter FY 2010 Financial Results 3Martek Announces Third Quarter FY 2010 Financial Results 4Martek Announces Third Quarter FY 2010 Financial Results 5Martek Announces Third Quarter FY 2010 Financial Results 6Martek Announces Third Quarter FY 2010 Financial Results 7Martek Announces Third Quarter FY 2010 Financial Results 8Martek Announces Third Quarter FY 2010 Financial Results 9Martek Announces Third Quarter FY 2010 Financial Results 10Martek Announces Third Quarter FY 2010 Financial Results 11Martek Announces Third Quarter FY 2010 Financial Results 12Martek Announces Third Quarter FY 2010 Financial Results 13Martek Announces Third Quarter FY 2010 Financial Results 14Ion Torrent Selected as World Economic Forum Technology Pioneer 2Ion Torrent Selected as World Economic Forum Technology Pioneer 3
(Date:4/20/2015)... 2015 The announcement comes as ... Records Management (GRM), Ireland,s foremost records ... Having built up an impressive track record of clients within ... within the records management sector in Dubai ... GCC staffbase and employ a further eight staff members at ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
(Date:4/13/2015)... YORK , April 13, 2015 ... by TechSci Research, "Global Biometrics Market Forecast & Opportunities, ... register a CAGR of around 14% till 2020. ... governments for large scale implementation and review of ... and launch of new products with greater efficiency, ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... study shows that the concentration of polycyclic aromatic,hydrocarbons (PAHs) ... much as,60 fold, with the highest levels in moist ... were in snus. Higher levels can be explained by ... source of the trace amounts of PAHs in snus ...
... Qi-Long Ying and a team of researchers have long been ... ways to encourage embryonic stem cells (ESCs) and epiblast stem ... stem cells. In a pair of studies published in ... EMBO Journal in August, Ying and his team revealed ...
... and physicians at The Johns Hopkins University will ... advance silicon applications in health care, beginning with ... broad range of clinical tests to be performed ... combine the Johns Hopkins clinical and research expertise ...
Cached Biology News:Polycyclic aromatic hydrocarbons in smokeless tobacco products 2USC researcher reveals how to better master stem cells' fate 2Johns Hopkins And Belgian research center to expand health care applications for silicon nanotech 2
Umbilical cord blood neutrophils, For immunohistochemistry (IHC)...
...
Request Info...
ChemiArray Human Cytokine Antibody Array VII, 60 cytokines per membrane...
Biology Products: